Result of Bortezomib Induction Therapy Prior to Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Cases in Mongolia

Abstract

Objectives: For last 5 years, we have focused on establishing autologous stem cell transplantation (ASCT) in Mongolia. Herein, we report on three Mongolian multiple myeloma (MM) cases treated with bortezomib and dexamethasone (VD) prior to ASCT. Methods: The MM diagnosis was confirmed by bone marrow aspiration, urine protein electrophoresis, and serum protein electrophoresis. Results: Circulating white blood cells appeared 8-10 days after ASCT. Platelet levels recovered 10 -15 days after ASCT. Conclusion: In our MM cases, the VD regimen prior to ASCT obtained good response rates without the impairment of stem cells.

Keywords

• stem cell
• transplantation
• bortezomib
• multiple myeloma